The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
ALS functional rating scale-revised (ALSFRS-R) score
The mean change of the ALSFRS-R total score
Time frame: 24 weeks
Deaths or tracheostomies
The cumulative proportion of deaths or tracheostomies
Time frame: 28 weeks
Proportion of regulatory T cells (Treg)
The mean change in the proportion of Tregs
Time frame: 24 weeks
Slow vital capacity (SVC)
The mean change of the SVC score
Time frame: 24 weeks
ALS assessment questionnaire (ALSAQ-40) score
The mean change of the ALS assessment questionnaire (ALSAQ-40) score
Time frame: 24 weeks
Adverse events (AEs)
The mean number of AEs
Time frame: 28 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.